Abemaciclib Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Abemaciclib Therapy, 2025, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6415/619_v4_Abemaciclib.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. 12

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane